KIORA PHARMACEUTICALS INC
Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapies for retinal diseases. Its product candidates include KIO-301, a small molecule being developed to restore vision in people with retinitis pigmentosa and other degenerative retinal diseases; KIO-104, an intravitreal treatment candidate for retinal inflammatory diseases such as diabetic macular edema and posterior non-infectious uveitis; and KIO-101, a topical eye drop candidate for ocular inflammation associated with autoimmune diseases. Kiora is conducting clinical development and works with partners on development and commercialization. Théa Open Innovation has global rights to co-develop and commercialize KIO-301 in ophthalmology, except for certain countries in Asia. Senju has an exclusive option to obtain a license for KIO-301 in certain Asian countries, including Japan and China. Kiora may earn payments tied to development, regulatory and commercial milestones and royalties. It is headquartered in Encinitas, California.
No SEC Form 4 filings for $KPRX in the last 30 days.
See all $KPRX insider activity →Kiora Pharmaceuticals reported Q3 2026 revenue of $1.0 million and a net loss of $1.75 million, with cash of $16.3 million. The company advanced KIO-401 development, submitted FDA meeting requests, and licensed KIO-301 rights in South Korea. Research and development expenses were $1.95 million, with collaboration credits of $886,000.
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update SAN DIEGO, California — November 12, 2026 — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today reported financial results for the third quarter e
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan • The oral small-molecule calpain inhibitor dem
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning KPRX (KIORA PHARMACEUTICALS INC). Coverage has skewed bearish: 0 bullish, 2 neutral, and 1 bearish.
Recent KPRX coverage spans earnings, corporate actions and financial news.
The earnings miss and modest revenue suggest short‑term pressure on the stock, while the advancement of KIO‑401 may offer upside if clinical data are positive.
The addition of KIO‑401 expands Kiora's pipeline and may improve future valuation.
The deal adds a late‑stage asset to Kiora's pipeline and creates near‑term cash inflow, which could lift sentiment and support the stock.
The licensing deal could unlock future revenue streams, prompting modest upside pressure.
Executive appointment may strengthen clinical pipeline execution but has limited immediate price impact.
AlphAI scores every news story that mentions KPRX with an AI model for sentiment and relevance, and aggregates insider trades from KIORA PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Kiora Pharmaceuticals reported Q3 2026 revenue of $1.0 million and a net loss of $1.75 million, with cash of $16.3 million. The company advanced KIO-401 development, submitted FDA meeting requests, and licensed KIO-301 rights in South Korea. Research and development expenses were $1.95 million, with collaboration credits of $886,000.
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update SAN DIEGO, California — November 12, 2026 — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today reported financial results for the third quarter e
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan • The oral small-molecule calpain inhibitor dem
Kiora Pharmaceuticals (KPRX) licensed KIO-401, a drug for central retinal artery occlusion (CRAO), from Senju. KIO-401 showed visual acuity improvement in Phase 2 and 3 trials in Japan. Kiora plans a multinational Phase 3 trial for CRAO in 2027 and a Phase 2b trial for NAION in 2028. No approved treatments exist for these conditions.
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the ad
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation ENCINITAS, Calif., August 19, 2026 — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora”) today announced that it
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 2026 results and a corporate update. It said Phase 2 ABACUS-2 enrollment for KIO-301 advanced into the higher-dose cohort and Phase 2 KLARITY enrollment for KIO-104 continued in the higher-dose group. Cash and short-term investments were about $16.8M, expected to fund operations into late 2028, and it secured up to $24.0M gross from a private placement.
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update ENCINITAS, Calif.—August 7, 2026 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided a
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exhibit101-2024equityplana.htm EX-10.1 Document KIORA PHARMACEUTICALS, INC. 2024 Equity Incentive Plan (As Amended on June 10, 2026) ARTICLE 1. INTRODUCTION The Plan was adopted by the Board on March 14, 2024, and will become effective immediately upon its approval by t
Kiora Pharmaceuticals announced the publication of its Phase 1 ABACUS-1 study results for KIO-301 in Nature Medicine, confirming the drug's safety and feasibility in late-stage retinitis pigmentosa patients. KIO-301, a molecular photoswitch, aims to restore light responsiveness regardless of genetic mutation. Building on these positive findings, the company has initiated a randomized, controlled Phase 2 clinical trial (ABACUS-2) to further evaluate higher doses and functional visual improvements.
